Clinical Trials Logo

Recurrent Melanoma clinical trials

View clinical trials related to Recurrent Melanoma.

Filter by:

NCT ID: NCT01131234 Completed - Clinical trials for Stage IV Breast Cancer

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors. Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate also may stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT01103635 Completed - Stage IV Melanoma Clinical Trials

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Start date: February 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as tremelimumab and CD40 agonist monoclonal antibody CP-870,893, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving tremelimumab together with CD 40 agonist monoclonal antibody CP-870, 893 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving tremelimumab together with CD40 agonist monoclonal antibody CP-870,893 in treating patients with metastatic melanoma.

NCT ID: NCT01037790 Completed - Clinical trials for HER2-positive Breast Cancer

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Start date: October 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with refractory solid tumors.

NCT ID: NCT00871481 Completed - Stage IV Melanoma Clinical Trials

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects of giving laboratory-treated T cells and ipilimumab together to see how well they work in treating patients with metastatic melanoma. Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving laboratory-treated T cells together with ipilimumab may kill more tumor cells

NCT ID: NCT00866177 Completed - Recurrent Melanoma Clinical Trials

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Start date: March 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00861913 Completed - Recurrent Melanoma Clinical Trials

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Start date: April 3, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects of pazopanib hydrochloride and to see how well it works in treating patients with metastatic melanoma that cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00669019 Completed - Stage IV Melanoma Clinical Trials

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Start date: July 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well saracatinib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT00655655 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

NCT ID: NCT00651157 Completed - Stage IV Melanoma Clinical Trials

Viral Therapy in Treating Patients With Metastatic Melanoma

Start date: April 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.

NCT ID: NCT00553306 Completed - Stage IV Melanoma Clinical Trials

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Laboratory-treated T cells may be able to kill tumor cells when they are put back into the body. Aldesleukin and cyclophosphamide may stimulate the immune system in different ways and stop tumor cells from growing. Giving laboratory-treated T cells together with aldesleukin after cyclophosphamide may be an effective treatment for melanoma. PURPOSE: This phase I/II trial is studying the side effects of giving laboratory-treated T cells together with aldesleukin after cyclophosphamide and to see how well they work in treating patients with stage IV melanoma.